Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2015 1
2022 1
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study.
Dua AB, Ford K, Fiore S, Pappas DA, Janak JC, Blachley T, Roberts-Toler C, Emeanuru K, Kremer JM, Kivitz A. Dua AB, et al. Among authors: ford k. Rheumatol Ther. 2023 Dec;10(6):1753-1768. doi: 10.1007/s40744-023-00609-2. Epub 2023 Oct 31. Rheumatol Ther. 2023. PMID: 37906399 Free PMC article.
Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
Sebba A, Bingham CO, Bykerk VP, Fiore S, Ford K, Janak JC, Pappas DA, Blachley T, Dave SS, Kremer JM, Yu M, Choy E. Sebba A, et al. Among authors: ford k. Clin Rheumatol. 2023 Aug;42(8):2037-2051. doi: 10.1007/s10067-023-06588-7. Epub 2023 Apr 15. Clin Rheumatol. 2023. PMID: 37060528 Free PMC article.
Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry.
Curtis JR, Fiore S, Ford K, Janak JC, Chang H, Pappas DA, Blachley T, Emeanuru K, Bykerk VP. Curtis JR, et al. Among authors: ford k. J Clin Rheumatol. 2023 Jun 1;29(4):e47-e51. doi: 10.1097/RHU.0000000000001956. Epub 2023 Mar 24. J Clin Rheumatol. 2023. PMID: 37000177
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity.
Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. Curtis JR, et al. Among authors: ford k. Arthritis Care Res (Hoboken). 2012 Dec;64(12):1794-803. doi: 10.1002/acr.21767. Arthritis Care Res (Hoboken). 2012. PMID: 22736476 Free PMC article.
12 results